News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Decision Resources, Inc. Release: The Majority of Surveyed U.S. Oncologists Identified FOLFIRINOX as the Most Efficacious Treatment for Advanced Pancreatic Cancer, When Compared to Other Currently Available Therapies


3/3/2011 10:26:02 AM

BURLINGTON, Mass.--(BUSINESS WIRE)--Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the majority of surveyed U.S. oncologists (57 percent) identified FOLFIRINOX* as the most efficacious treatment for advanced pancreatic cancer, when compared to other currently available agents. Patients with advanced pancreatic cancer who received FOLFIRINOX experienced a considerably longer median overall survival compared with patients who received gemcitabine (Eli Lilly’s Gemzar, generics) monotherapy.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES